Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease

作者:Lee Belinda T; Ahmed Faheemuddin A; Hamm L Lee; Teran Federico J; Chen Chung Shiuan; Liu Yanxi; Shah Kamal; Rifai Nader; Batuman Vecihi; Simon Eric E; He Jiang; Chen Jing*
来源:BMC Nephrology, 2015, 16(1): 77.
DOI:10.1186/s12882-015-0068-7

摘要

Background: We studied the association of inflammatory biomarkers including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) with chronic kidney disease (CKD). Methods: We conducted a case-control study among 201 CKD patients and 201 community-based controls in the greater New Orleans area. CKD was defined as estimated-glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) or albuminuria >= 30 mg/24-h. Serum CRP, TNF-alpha, and IL-6 were measured using standard methods. Multivariable regression models were used to examine associations between the inflammatory biomarkers and CKD adjusting for important CKD risk factors, history of cardiovascular disease, and use of antihypertensive, antidiabetic, and lipid-lowering agents and aspirin. Results: The multivariable-adjusted medians (interquartile-range) were 2.91 (1.47, 5.24) mg/L in patients with CKD vs. 1.91 (0.99, 3.79) mg/L in controls without CKD (p = 0.39 for group difference) for CRP; 1.86 (1.51, 2.63) pg/mL vs. 1.26 (1.01, 1.98) pg/mL (p < 0.0001) for TNF-alpha; and 2.53 (1.49, 4.42) pg/mL vs. 1.39 (0.95, 2.15) pg/mL (p = 0.04) for IL-6, respectively. Compared to the lowest tertile, the highest tertile of TNF-alpha (OR 7.1, 95 % CI 3.2 to 15.5) and IL-6 (OR 2.5, 95 % CI 1.1 to 5.5) were significantly associated with higher odds of CKD in multivariable-adjusted models. Additionally, higher TNF-alpha and IL-6 were independently and significantly associated with lower eGFR and higher albuminuria. Conclusions: Our data suggest that TNF-alpha and IL-6, but not CRP, are associated with the prevalence and severity of CKD, independent from established CKD risk factors, history of cardiovascular disease, and use of antihypertensive, antidiabetic, and lipid-lowering agents and aspirin.

  • 出版日期2015-5-30